ADOPTIVE TRANSFER OF MART-1 F5 TCR ENGINEERED PERIPHERAL BLOOD MONONUCLEAR CELLS

$13,844M01FY2010RRNIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Paper 38913861 Paper 38706462 Paper 38554018 Paper 38410951 Paper 38190104 Paper 38063529 Paper 37817282 Paper 37506298 Paper 36610253 Paper 36179266 Paper 36001419 Paper 35779438 Paper 35765986 Paper 35617264 Paper 35483500 Paper 34707329 Paper 34534914 Paper 34534857 Paper 34397408 Paper 34337570 Paper 34323265 Paper 33612145 Paper 33536949 Paper 33504263 Paper 33465008 Paper 33310624 Paper 33153830 Paper 33038344 Paper 32945536 Paper 32896862 Paper 32860348 Paper 32810694 Paper 32659693 Paper 32212770 Paper 31812102 Paper 31746534 Paper 31542635 Paper 31255951 Paper 31230465 Paper 31200127 Paper 31168579 Paper 31105380 Paper 31070400 Paper 30943214 Paper 30783672 Paper 30605796 Paper 30597101 Paper 30348285 Paper 30165409 Paper 29915079 Paper 29878042 Paper 29807211 Paper 29735350 Paper 29704001 Paper 29527482 Paper 29466893 Paper 29353512 Paper 29349266 Paper 29172602 Paper 29136240 Paper 29057014 Paper 29056783 Paper 28764909 Paper 28732236 Paper 28711699 Paper 28659244 Paper 28651371 Paper 28601752 Paper 28513316 Paper 28486177 Paper 28351939 Paper 28346146 Paper 28315111 Paper 28284787 Paper 28262939 Paper 28190951 Paper 28183529 Paper 28164150 Paper 27990494 Paper 27938923 Paper 27938909 Paper 27896947 Paper 27823815 Paper 27774807 Paper 27677166 Paper 27634830 Paper 27631613 Paper 27614114 Paper 27583527 Paper 27570892 Paper 27516421 Paper 27421618 Trial NCT00690196 Trial NCT00600561 Patent 8207120 Patent 8044026 Patent 7884066 Patent 7776361 Patent 7687462 Patent 7052856

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In our approach we intend to deliver a MART-1 F5 TCR transgenic cell dose that will be one to two logs lower than the NCI protocol, and there is no experimental or clinical evidence of a decreased cell dose-related toxicity effect. Therefore, there is no need for a standard phase 1 dose escalation clinical trial design

View original record on NIH RePORTER →